Konrad Zielinski lost his natural speech to cancer years ago while studying as a student at the University of Warsaw. People who undergo total voice box removal typically rely on handheld artificial electro-larynx devices that produce flat, robotic tones, or surgically implanted voice prostheses that require ongoing maintenance to prevent medical complications. Driven by his personal experience, Zielinski completed a doctorate focusing on bionic systems to create a non-invasive wearable that restores natural vocal intonation without requiring additional surgery.
In 2023, Zielinski launched Uhura Bionics, an early-stage startup selected to showcase its wearable technology at major industry conferences. The company offers two main wearable models: a standard entry-level version and a high-end model named Whitney, honoring iconic singer Whitney Houston. Zielinski envisions a future where people who lose their voice box use wearable speech tools as naturally as people with vision loss wear prescription eyeglasses.
Traditional electro-larynx devices create metallic, monotonic speech that strips away personal identity and emotional nuance. Uhura’s technology captures subtle muscular signals and translates them into natural vocal cadence, letting users express emotion, laugh, and vary their speaking pitch. While current output retains a faint synthetic undertone, adding natural intonation gives users a more authentic human voice.
The development roadmap at Uhura Bionics focuses on expanding custom voice profiles. Engineering teams are building higher-pitched voice models tailored for female users alongside deep personalization features so individual users do not sound identical. For now, Uhura sells its hardware as wellness equipment, requiring out-of-pocket payments ranging from $500 for the basic model to $1,500 for the premium Whitney edition.
To improve accessibility, the startup is actively pursuing Class I medical device status across European and American regulatory frameworks. Securing official medical device classification allows insurance providers to cover partial hardware costs, making advanced speech restoration available to a wider population. Zielinski estimates the total market size for devices supporting laryngectomees at roughly $2 billion globally, with additional growth potential as the underlying technology expands to treat broader speech disorders.
Uhura faces competition from modern medical tech firms like Atos Medical and specialized startups like Laronix. However, Zielinski remains confident that providing emotional expression through non-invasive hardware sets his approach apart. Demonstrating these capabilities live on stage proves that non-invasive wearable devices can bridge the gap between mechanical speech tools and natural human vocal expression.
Restoring pitch, tone, and emotional inflection transforms how individuals recover from major surgeries. Standard voice prostheses force users to compromise between surgical risks and flat, robotic speech. Building wearable hardware that interprets muscle signals without invasive procedures gives patients a safe, reliable path to regain their vocal identity. As non-invasive medical hardware advances, speech restoration platforms will give millions of patients around the world their human voices back.